Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000812707 | SCV000953029 | uncertain significance | Charcot-Marie-Tooth disease dominant intermediate B | 2023-11-14 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 232 of the DNM2 protein (p.Ile232Thr). This variant is present in population databases (rs749672066, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with DNM2-related conditions. ClinVar contains an entry for this variant (Variation ID: 656321). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on DNM2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Mayo Clinic Laboratories, |
RCV001507412 | SCV001712953 | uncertain significance | not provided | 2019-10-06 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV002507416 | SCV002816493 | uncertain significance | Charcot-Marie-Tooth disease dominant intermediate B; Autosomal dominant centronuclear myopathy; Fetal akinesia-cerebral and retinal hemorrhage syndrome | 2022-04-14 | criteria provided, single submitter | clinical testing |